This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Prostate Cancer
and you are
between 20 and 73
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

Primary Objective: - To assess the tolerability at global doses Secondary Objectives: - Safety - Pharmacokinetics - Efficacy

Provided treatments

  • Drug: Cabazitaxel (XRP6258)
  • Drug: prednisolone

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01324583. The sponsor of the trial is Sanofi and it is looking for 48 volunteers for the current phase.
Official trial title:
An Open Label, Dose Escalation, Safety and Pharmacokinetics Phase I Study With Cabazitaxel Administered as a 1-hour Intravenous Infusion Every 3 Weeks in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer